Liver Transplantation Clinical Trial
Official title:
Endoscopic Evaluation in Transplantation Candidates - Frequency and Prognostic Relevance of Upper and Lower Gastrointestinal Tract Findings
Verified date | October 2011 |
Source | Hannover Medical School |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ethics Commission |
Study type | Observational |
In consideration of the limited supply of donor organs, the careful selection of transplant
candidates is essential to optimize patient outcome after transplantation. Therefore an
extensive evaluation of transplant candidates including among others
esophagogastroduodenoscopy (EGD) and colonoscopy has been implemented in our centre. The
data regarding the prevalence of upper and lower gastrointestinal (GI) pathology in
transplant candidates are contradictory and are based on only a few retrospective studies,
which often include only a subgroup of transplant candidates. The goal of this project is a
prospective evaluation of the frequency of GI pathologies in transplant candidates with
specific focus on the following questions:
1. Are there GI-pathologies that occur at a higher prevalence in transplant candidates
than described in the general population and is there an increase of GI-pathologies
since the introduction of the urgency-based organ allocation leading to sicker
transplant candidates?
2. What is the influence of endoscopic findings on patient management before
transplantation?
3. Which risk factors can be identified that predict the presence of GI-lesions?
4. Is there a subgroup of patients, in which screening colonoscopy before liver
transplantation can not be recommended considering the cost/benefit ratio?
5. Is there a correlation of endoscopic findings with outcome after liver transplantation
or with gastrointestinal complications during or after transplantation (e.g.
gastrointestinal bleeding, perforation or gastrointestinal malignancy)?
Status | Completed |
Enrollment | 300 |
Est. completion date | December 2010 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 80 Years |
Eligibility |
Inclusion Criteria: - Patients who receive upper and/or lower endoscopy during evaluation for transplantation Exclusion Criteria: - patient already on waiting list |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Germany | Hannover Medical School | Hannover |
Lead Sponsor | Collaborator |
---|---|
Hannover Medical School |
Germany,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 | |
Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 |